Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma

Taku Kikuchi, Takehiko Mori, Yuya Koda, Sumiko Kohashi, Jun Kato, Takaaki Toyama, Tomonori Nakazato, Yoshinobu Aisa, Takayuki Shimizu, Shinichiro Okamoto

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We retrospectively evaluated single-institute outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) with a reduced-intensity conditioning regimen consisting of fludarabine (125 mg/m2) and melphalan (140 mg/m2) for multiple myeloma. Twenty-three patients (median age: 46 years) were evaluated. Stem cell sources were bone marrow or peripheral blood stem cells from siblings (n = 4) and bone marrow from unrelated donors (n = 19). For graft-versus-host disease prophylaxis, cyclosporine A or tacrolimus with short-term methotrexate was given. Disease status at time of transplant was complete response in four patients, very good partial or partial response in 13, and stable or progressive disease in six. The median follow-up period of 7 survivors at analysis was 73.2 months (range 46.0–158.9 months). During the follow-up, disease recurrence or progression was observed in 21 patients, and was primary causes of death in 88 % of the patients. The 5-year overall survival and progression-free survival rates were 38.6 % (95 % CI 19.3–57.7 %) and 5.4 % (95 % CI 0.4–21.6 %), respectively. Although allo-HSCT with this conditioning could be safely performed, further refinement of this approach aiming at more effective eradication of myeloma cells is clearly warranted.

Original languageEnglish
Pages (from-to)670-677
Number of pages8
JournalInternational Journal of Hematology
Volume102
Issue number6
DOIs
Publication statusPublished - 2015 Dec 1

Fingerprint

Hematopoietic Stem Cell Transplantation
Multiple Myeloma
Transplantation Conditioning
Bone Marrow
Unrelated Donors
Melphalan
Tacrolimus
Graft vs Host Disease
Methotrexate
Cyclosporine
Disease-Free Survival
Survivors
Siblings
Cause of Death
Stem Cells
Survival Rate
Transplants
Recurrence
Survival

Keywords

  • Allogeneic hematopoietic stem cell transplantation
  • Fludarabine
  • Melphalan
  • Multiple myeloma
  • Reduced-intensity conditioning

ASJC Scopus subject areas

  • Hematology

Cite this

Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma. / Kikuchi, Taku; Mori, Takehiko; Koda, Yuya; Kohashi, Sumiko; Kato, Jun; Toyama, Takaaki; Nakazato, Tomonori; Aisa, Yoshinobu; Shimizu, Takayuki; Okamoto, Shinichiro.

In: International Journal of Hematology, Vol. 102, No. 6, 01.12.2015, p. 670-677.

Research output: Contribution to journalArticle

@article{1e27c45f702e4997b556bf76e914700c,
title = "Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma",
abstract = "We retrospectively evaluated single-institute outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) with a reduced-intensity conditioning regimen consisting of fludarabine (125 mg/m2) and melphalan (140 mg/m2) for multiple myeloma. Twenty-three patients (median age: 46 years) were evaluated. Stem cell sources were bone marrow or peripheral blood stem cells from siblings (n = 4) and bone marrow from unrelated donors (n = 19). For graft-versus-host disease prophylaxis, cyclosporine A or tacrolimus with short-term methotrexate was given. Disease status at time of transplant was complete response in four patients, very good partial or partial response in 13, and stable or progressive disease in six. The median follow-up period of 7 survivors at analysis was 73.2 months (range 46.0–158.9 months). During the follow-up, disease recurrence or progression was observed in 21 patients, and was primary causes of death in 88 {\%} of the patients. The 5-year overall survival and progression-free survival rates were 38.6 {\%} (95 {\%} CI 19.3–57.7 {\%}) and 5.4 {\%} (95 {\%} CI 0.4–21.6 {\%}), respectively. Although allo-HSCT with this conditioning could be safely performed, further refinement of this approach aiming at more effective eradication of myeloma cells is clearly warranted.",
keywords = "Allogeneic hematopoietic stem cell transplantation, Fludarabine, Melphalan, Multiple myeloma, Reduced-intensity conditioning",
author = "Taku Kikuchi and Takehiko Mori and Yuya Koda and Sumiko Kohashi and Jun Kato and Takaaki Toyama and Tomonori Nakazato and Yoshinobu Aisa and Takayuki Shimizu and Shinichiro Okamoto",
year = "2015",
month = "12",
day = "1",
doi = "10.1007/s12185-015-1873-2",
language = "English",
volume = "102",
pages = "670--677",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "6",

}

TY - JOUR

T1 - Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma

AU - Kikuchi, Taku

AU - Mori, Takehiko

AU - Koda, Yuya

AU - Kohashi, Sumiko

AU - Kato, Jun

AU - Toyama, Takaaki

AU - Nakazato, Tomonori

AU - Aisa, Yoshinobu

AU - Shimizu, Takayuki

AU - Okamoto, Shinichiro

PY - 2015/12/1

Y1 - 2015/12/1

N2 - We retrospectively evaluated single-institute outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) with a reduced-intensity conditioning regimen consisting of fludarabine (125 mg/m2) and melphalan (140 mg/m2) for multiple myeloma. Twenty-three patients (median age: 46 years) were evaluated. Stem cell sources were bone marrow or peripheral blood stem cells from siblings (n = 4) and bone marrow from unrelated donors (n = 19). For graft-versus-host disease prophylaxis, cyclosporine A or tacrolimus with short-term methotrexate was given. Disease status at time of transplant was complete response in four patients, very good partial or partial response in 13, and stable or progressive disease in six. The median follow-up period of 7 survivors at analysis was 73.2 months (range 46.0–158.9 months). During the follow-up, disease recurrence or progression was observed in 21 patients, and was primary causes of death in 88 % of the patients. The 5-year overall survival and progression-free survival rates were 38.6 % (95 % CI 19.3–57.7 %) and 5.4 % (95 % CI 0.4–21.6 %), respectively. Although allo-HSCT with this conditioning could be safely performed, further refinement of this approach aiming at more effective eradication of myeloma cells is clearly warranted.

AB - We retrospectively evaluated single-institute outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) with a reduced-intensity conditioning regimen consisting of fludarabine (125 mg/m2) and melphalan (140 mg/m2) for multiple myeloma. Twenty-three patients (median age: 46 years) were evaluated. Stem cell sources were bone marrow or peripheral blood stem cells from siblings (n = 4) and bone marrow from unrelated donors (n = 19). For graft-versus-host disease prophylaxis, cyclosporine A or tacrolimus with short-term methotrexate was given. Disease status at time of transplant was complete response in four patients, very good partial or partial response in 13, and stable or progressive disease in six. The median follow-up period of 7 survivors at analysis was 73.2 months (range 46.0–158.9 months). During the follow-up, disease recurrence or progression was observed in 21 patients, and was primary causes of death in 88 % of the patients. The 5-year overall survival and progression-free survival rates were 38.6 % (95 % CI 19.3–57.7 %) and 5.4 % (95 % CI 0.4–21.6 %), respectively. Although allo-HSCT with this conditioning could be safely performed, further refinement of this approach aiming at more effective eradication of myeloma cells is clearly warranted.

KW - Allogeneic hematopoietic stem cell transplantation

KW - Fludarabine

KW - Melphalan

KW - Multiple myeloma

KW - Reduced-intensity conditioning

UR - http://www.scopus.com/inward/record.url?scp=84949105884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949105884&partnerID=8YFLogxK

U2 - 10.1007/s12185-015-1873-2

DO - 10.1007/s12185-015-1873-2

M3 - Article

VL - 102

SP - 670

EP - 677

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 6

ER -